Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Belimumab versus placebo for idiopathic membranous nephropathy
NL-OMON37265Phase 2Withdrawn
- Sponsor
- GSK
- Start
- Oct 2012
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in idiopathic membranous glomerulonephritis (IMG) comparing Belimumab plus supportive therapy with Placebo plus supportive therapy (2 arms). Primary endpoint: Incidence of remission. Planned start Oct 2012; status: withdrawn.
02
Drugs
belimumab
03
Conditions
idiopathic membranous glomerulonephritis (IMG)
Beyond the preview
Go deeper on NL-OMON37265.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON37265.